---
anonymous_label: OUT-18
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: 5981d94ab662a8b8f7d8e33cad42e46a0a9ab1f11139862517deb739dbaa38a2
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-18

I recommend that you commit to the **Claim File Review**.

### Reasoning and Trade-offs
Your current situation is a classic "false positive" signal. You have strong lagging indicators (bookings, renewals) but alarming leading indicators (adjuster abandonment, "ghost" usage by managers, and upcoming churn in regional carriers).

The expansion bookings are contaminated by a temporary pricing bundle—meaning the customers bought a *deal*, not necessarily a *solution*. The usage spike is misleading; managers using the tool for "samples" in enablement meetings is a training activity, not a workflow integration.

You are facing a critical "Value Gap": the tool provides a suggestion, but the user cannot justify that suggestion to their internal reviewer (especially in health-liability). If a B2B tool creates more work for the user (explaining the AI) than it saves them, they will eventually churn regardless of the initial sales pitch.

**Why this over the others?**
*   **Against Scaling Broadly:** This is reckless. You have evidence of abandonment and impending churn. Scaling a leaky bucket only accelerates the crash.
*   **Against the Usage Quality Sprint:** This measures *that* people are leaving, but not *why*. You already know they fall back to manual notes. More dashboards won't tell you how to fix the logic or the explainability problem.
*   **Against the Commercial Cleanroom:** This is a sales experiment. While it would prove that SignalPath isn't driving the renewals, it doesn't provide a path to fixing the product. You don't need to prove the sales pitch is misleading; you already have enough evidence of that.
*   **Against Narrowing to Health-Liability:** This is premature. You don't know if the "explainability" issue is a universal flaw in SignalPath or a specific regulatory hurdle for health-liability.

The **Claim File Review** is the only option that treats the product as a workflow tool rather than a sales asset. By seeing exactly where suggestions are overridden or rewritten, you move from "usage percentages" to "utility truths." You will discover if the tool is actually wrong, or if it's right but "un-explainable."

### The strongest reason against this recommendation
The Claim File Review is slow, manual, and "un-scalable." It provides a small sample size compared to the Usage Quality Sprint. By choosing this, you sacrifice the ability to provide the board with a high-confidence, company-wide quantitative metric on retention. You are trading "big data" (which is currently lying to you) for "thick data" (which is harder to present in a board deck).

### Observable evidence that would change my mind
I would pivot to the **Commercial Cleanroom** if you discovered that the "regional carrier churn" was not caused by product failure, but by a specific change in their procurement policy or a competitor's aggressive pricing. If the product is actually working (as evidenced by the adjusters) but the *buyers* are simply refusing to pay for it, you have a pricing/packaging problem, not a product-market fit problem. In that case, the Cleanroom is the only way to isolate the commercial value.
